Zydus can launch ulcer drug in US, patent litigation settled

Drug firm Zydus Cadila said the patent litigation relating to Allergan's Delzicol, used to treat ulcerative colitis, has been settled.

The patent litigation relating to Allergan's Delzicol (mesalamine) has been settled, Zydus Cadila said in a statement.

"As a result of the settlement, and if approved by FDA, its US subsidiary, Zydus Pharmaceuticals (USA) Inc, will be able to market its generic version of Delzicol in the US beginning on March 1, 2020, or earlier under certain circumstances," it added.